Latest 3Sbio Inc. (SSRX) Headlines
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Secretary of Agriculture Declaration Deadline Approaching in Mississippi for SBA Working Capital Loans
PR Newswire - Mon Mar 03, 9:39AM CST
The U.S. Small Business Administration is reminding small businesses, small agricultural cooperatives, small businesses engaged in aquaculture and most private non-profit organizations of all sizes that March 31 is the filing deadline for federal economic injury disaster loans in Mississippi as a result of the freeze on March 25 - 29, 2013.
Invesco PowerShares Announces a Special Dividend for PowerShares QQQ
Marketwire - Fri Feb 21, 6:48PM CST
Invesco PowerShares Capital Management LLC, a leading global provider of exchange-traded funds (ETFs), announced today that PowerShares QQQ expects to issue a special dividend payment on Friday, March, 7, 2014.
3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
PR Newswire - Tue Oct 29, 5:09AM CDT
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). 3SBio intends to seek approval from the CFDA to undertake phase one clinical trials in China.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Metastatic Melanoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mttj8/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2012" report to their offering. This data provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of products based on various stages of development ranging from discovery till registration stages - A feature on pipeline projects on the basis of monotherapy and combined therapeutics - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type - Key discontinued pipeline projects - Latest news and deals relating to the products Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Metastatic Melanoma Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Melanoma Companies Involved in Metastatic Melanoma Therapeutics Development Metastatic Melanoma - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - 3SBio Inc - AVAX Technologies - Abbott Laboratories - Antigenics - BioAlliance Pharma - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics - Eli Lilly and Company - F. Hoffmann-La Roche - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Incyte Corporation - Lorus Therapeutics - Millennium Pharmaceuticals - Molecular Insight Pharmaceuticals - Morphotek - Northwest Biotherapeutics - Novartis AG - Oncolytics Biotech - Ono Pharmaceutical - Osta Biotechnologies - Oxford BioMedica - Pain Therapeutics - Progen Pharmaceuticals Limited - Provectus Pharmaceuticals - Summit Corporation - Vical Incorporated - Viralytics For more information visit http://www.researchandmarkets.com/research/5mttj8/metastatic
3SBio Shares Up 36.8% Since SmarTrend's Buy Recommendation (SSRX)
Comtex SmarTrend(R) - Fri Jul 12, 4:51PM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 11 months, 3SBio has returned 36.77% as of today's recent price of $16.59.
Shares of SSRX Up 36.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jul 05, 10:58AM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 11 months, 3SBio has returned 36.77% as of today's recent price of $16.59.
Uptrend Call Working As 3SBio Stock Rises 36.8% (SSRX)
Comtex SmarTrend(R) - Thu Jun 20, 9:38AM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 10 months, 3SBio has returned 36.77% as of today's recent price of $16.59.
Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen
3SBio Inc. Announces Completion of Merger
PR Newswire - Thu May 30, 7:50AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced today the completion of the merger (the "Merger") contemplated by the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"), and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Merger Agreement"). As a result of the Merger, the Company became a wholly-owned subsidiary of Parent.
3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement
PR Newswire - Fri May 24, 12:51AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that, at an extraordinary general meeting held today (the "EGM"), the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"), and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Amended Merger Agreement"), pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the "Merger"), and to authorize and approve all transactions contemplated by the Amended Merger Agreement, including the Merger.
3SBio Has Returned 36.0% Since SmarTrend Recommendation (SSRX)
Comtex SmarTrend(R) - Wed May 08, 10:58AM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 9 months, 3SBio has returned 36.03% as of today's recent price of $16.50.
3SBio Inc. Announces Extraordinary General Meeting of Shareholders
PR Newswire - Thu May 02, 12:24AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing, and marketing biopharmaceutical products, today announced that its extraordinary general meeting of shareholders (the "EGM") that was previously adjourned on April 25, 2013 will be held on May 24, 2013, at 10:00am, Beijing time, at the Company's offices located at 15/A-D, Huaxin International Tower, No. 219, Qingnian Ave., Shenhe District, Shenyang 110016, People's Republic of China. At the EGM, shareholders will consider and vote on the proposal to authorize and approve the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"),
3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
PR Newswire - Wed May 01, 7:32AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has filed the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2012 with the U.S. Security and Exchange Commission on April 30, 2013. The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov or on the Investor section of the Company's website www.3sbio.com. Shareholders may also receive a hard copy of the annual report free of charge upon request.
3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
PR Newswire - Thu Apr 25, 3:30AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that, at the duly convened extraordinary general meeting of shareholders ("EGM") held at 10:00am Beijing time on April 25, 2013, Dr. Jing Lou, as the chairman of EGM, declared that EGM be adjourned to a later date as soon as practicable in order to allow additional time for the Company to provide updated information to the shareholders regarding the Agreement and Plan of Merger, dated as of February 8, 2013, by and among Decade Sunshine Limited, Decade Sunshine Merger Sub and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Amended Merger Agreement"). Apart from the adjournment of the EGM, no other business was conducted at EGM. The Company expects to file with the Securities and Exchange Commission (the "SEC") and send to shareholders prom
Global Biosimilars Market 2014-2018: Patent Expirations and More
M2 - Wed Mar 05, 11:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/jggmhc/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd. Commenting on the report, an analyst from the team said: The manufacture of biosimilar products requires specialized capabilities, meticulous planning, highly skilled staff, and significant financial investment in equipment, technology, materials, and personnel. Therefore, the complexities and costs involved in the biosimilar development rises along with the dip in their profit margins, hampering the overall success of manufacturing biosimilar products. Thus, many vendors are increasingly turning to CMOs and CROs that have already gained proficiency in the field of manufacturing biosimilar products. The wealth of knowledge, experience, understanding, technology, skills and financial control that CMOs and CROs can provide to manufacturers, make this a solution that many vendors are using at present. These organizations employ well-trained professionals to develop and validate analytical methods, providing pharmaceutical companies with a feasible way of remaining competitive and financially viable. This new trend is expected to have a positive impact on the growth of the market over the next few years. For more information visit http://www.researchandmarkets.com/research/jggmhc/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Secretary of Agriculture Declaration Deadline Approaching in Mississippi for SBA Working Capital Loans
PR Newswire - Mon Mar 03, 9:39AM CST
The U.S. Small Business Administration is reminding small businesses, small agricultural cooperatives, small businesses engaged in aquaculture and most private non-profit organizations of all sizes that March 31 is the filing deadline for federal economic injury disaster loans in Mississippi as a result of the freeze on March 25 - 29, 2013.
Invesco PowerShares Announces a Special Dividend for PowerShares QQQ
Marketwire - Fri Feb 21, 6:48PM CST
Invesco PowerShares Capital Management LLC, a leading global provider of exchange-traded funds (ETFs), announced today that PowerShares QQQ expects to issue a special dividend payment on Friday, March, 7, 2014.
3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
PR Newswire - Tue Oct 29, 5:09AM CDT
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD'). 3SBio intends to seek approval from the CFDA to undertake phase one clinical trials in China.
Cervical Cancer - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lpg7wz/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2013" report to their offering. 'Cervical Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. Scope - A snapshot of the global therapeutic scenario for Cervical Cancer. - A review of the Cervical Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cervical Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned F. Hoffmann-La Roche Ltd. Helix BioPharma Corp. Sanofi-Aventis GlaxoSmithKline plc Gilead Sciences, Inc. Daiichi Sankyo Company, Ltd Amorfix Life Sciences Ltd. MediGene AG Nanotherapeutics, Inc. Novartis AG Chong Kun Dang Pharmaceutical Taiho Pharmaceutical Co., Ltd. Zeria Pharmaceutical Co Ltd Genmab A/S CEL-SCI Corporation Advaxis, Inc. 3SBio Inc. Dendreon Corporation Transgene SA Antigen Express, Inc. Shantha Biotechnics Limited and many more... For more information visit http://www.researchandmarkets.com/research/lp...cal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Metastatic Melanoma - Pipeline Review, H2 2012
M2 - Mon Aug 12, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5mttj8/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H2 2012" report to their offering. This data provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Melanoma. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Metastatic Melanoma - A review of the Metastatic Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Coverage of products based on various stages of development ranging from discovery till registration stages - A feature on pipeline projects on the basis of monotherapy and combined therapeutics - Coverage of the Metastatic Melanoma pipeline on the basis of route of administration and molecule type - Key discontinued pipeline projects - Latest news and deals relating to the products Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Metastatic Melanoma Overview Therapeutics Development An Overview of Pipeline Products for Metastatic Melanoma Companies Involved in Metastatic Melanoma Therapeutics Development Metastatic Melanoma - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - 3SBio Inc - AVAX Technologies - Abbott Laboratories - Antigenics - BioAlliance Pharma - Bristol-Myers Squibb Company - Celgene Corporation - Celldex Therapeutics - Eli Lilly and Company - F. Hoffmann-La Roche - Genentech - GlaxoSmithKline - Hemispherx Biopharma - Incyte Corporation - Lorus Therapeutics - Millennium Pharmaceuticals - Molecular Insight Pharmaceuticals - Morphotek - Northwest Biotherapeutics - Novartis AG - Oncolytics Biotech - Ono Pharmaceutical - Osta Biotechnologies - Oxford BioMedica - Pain Therapeutics - Progen Pharmaceuticals Limited - Provectus Pharmaceuticals - Summit Corporation - Vical Incorporated - Viralytics For more information visit http://www.researchandmarkets.com/research/5mttj8/metastatic
3SBio Shares Up 36.8% Since SmarTrend's Buy Recommendation (SSRX)
Comtex SmarTrend(R) - Fri Jul 12, 4:51PM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 11 months, 3SBio has returned 36.77% as of today's recent price of $16.59.
Shares of SSRX Up 36.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jul 05, 10:58AM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 11 months, 3SBio has returned 36.77% as of today's recent price of $16.59.
Uptrend Call Working As 3SBio Stock Rises 36.8% (SSRX)
Comtex SmarTrend(R) - Thu Jun 20, 9:38AM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 10 months, 3SBio has returned 36.77% as of today's recent price of $16.59.
Gynecological Cancer - Pipeline Review, H1 2013 Features Players such as Amgen Inc., Bionomics Limited and Novogen Limited
M2 - Wed Jun 05, 9:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2rhvd5/gynecological) has announced the addition of the "Gynecological Cancer - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gynecological Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gynecological Cancer. Gynecological Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scen
3SBio Inc. Announces Completion of Merger
PR Newswire - Thu May 30, 7:50AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced today the completion of the merger (the "Merger") contemplated by the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"), and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Merger Agreement"). As a result of the Merger, the Company became a wholly-owned subsidiary of Parent.
3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement
PR Newswire - Fri May 24, 12:51AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that, at an extraordinary general meeting held today (the "EGM"), the Company's shareholders voted in favor of the proposal to authorize and approve the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"), and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Amended Merger Agreement"), pursuant to which Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the "Merger"), and to authorize and approve all transactions contemplated by the Amended Merger Agreement, including the Merger.
3SBio Has Returned 36.0% Since SmarTrend Recommendation (SSRX)
Comtex SmarTrend(R) - Wed May 08, 10:58AM CDT
SmarTrend identified an Uptrend for 3SBio (NASDAQ:SSRX) on August 20th, 2012 at $12.13. In approximately 9 months, 3SBio has returned 36.03% as of today's recent price of $16.50.
3SBio Inc. Announces Extraordinary General Meeting of Shareholders
PR Newswire - Thu May 02, 12:24AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing, and marketing biopharmaceutical products, today announced that its extraordinary general meeting of shareholders (the "EGM") that was previously adjourned on April 25, 2013 will be held on May 24, 2013, at 10:00am, Beijing time, at the Company's offices located at 15/A-D, Huaxin International Tower, No. 219, Qingnian Ave., Shenhe District, Shenyang 110016, People's Republic of China. At the EGM, shareholders will consider and vote on the proposal to authorize and approve the previously announced agreement and plan of merger dated February 8, 2013, among Decade Sunshine Limited, an exempted company with limited liability incorporated under the laws of the Cayman Islands ("Parent"), Decade Sunshine Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a direct wholly owned subsidiary of Parent ("Merger Sub"),
3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2012
PR Newswire - Wed May 01, 7:32AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has filed the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2012 with the U.S. Security and Exchange Commission on April 30, 2013. The annual report on Form 20-F, which contains its audited financial statements, can be accessed on the SEC's website at http://www.sec.gov or on the Investor section of the Company's website www.3sbio.com. Shareholders may also receive a hard copy of the annual report free of charge upon request.
3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
PR Newswire - Thu Apr 25, 3:30AM CDT
3SBio Inc. (NASDAQ: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that, at the duly convened extraordinary general meeting of shareholders ("EGM") held at 10:00am Beijing time on April 25, 2013, Dr. Jing Lou, as the chairman of EGM, declared that EGM be adjourned to a later date as soon as practicable in order to allow additional time for the Company to provide updated information to the shareholders regarding the Agreement and Plan of Merger, dated as of February 8, 2013, by and among Decade Sunshine Limited, Decade Sunshine Merger Sub and the Company, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of April 24, 2013 (the "Amended Merger Agreement"). Apart from the adjournment of the EGM, no other business was conducted at EGM. The Company expects to file with the Securities and Exchange Commission (the "SEC") and send to shareholders prom
